New insider Alexander Margaret A. claimed ownership of 28,125 shares (SEC Form 3)
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 09/09/2024 |
3. Issuer Name and Ticker or Trading Symbol
Ovid Therapeutics Inc. [ OVID ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 28,125(1) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Employee Stock Option (right to buy) | (2) | 08/02/2031 | Common Stock | 70,000 | $3.73 | D | |
| Employee Stock Option (right to buy) | (3) | 08/05/2031 | Common Stock | 2,021 | $3.74 | D | |
| Employee Stock Option (right to buy) | (4) | 02/03/2032 | Common Stock | 100,000 | $2.72 | D | |
| Employee Stock Option (right to buy) | (5) | 04/08/2032 | Common Stock | 10,000 | $3.22 | D | |
| Employee Stock Option (right to buy) | (6) | 02/23/2033 | Common Stock | 175,000 | $2.5 | D | |
| Employee Stock Option (right to buy) | (7) | 02/22/2034 | Common Stock | 168,750 | $3.68 | D | |
| Employee Stock Option (right to buy) | (8) | 07/30/2034 | Common Stock | 315,000 | $1.05 | D | |
| Explanation of Responses: |
| 1. Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on February 22, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date. |
| 2. 25% of the shares subject to the Stock Option vested and became exercisable on August 2, 2022 and the remaining shares vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. |
| 3. Fully vested and exercisable. |
| 4. 25% of the shares subject to the Stock Option vested and became exercisable on February 3, 2023 and the remaining shares vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. |
| 5. 25% of the shares subject to the Stock Option vested and became exercisable on April 8, 2023 and the remaining shares vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. |
| 6. 25% of the shares subject to the Stock Option vested and became exercisable on February 23, 2024 and the remaining shares vested or will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. |
| 7. 25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. |
| 8. 50% of the shares subject to the Stock Option will vest and become exercisable on July 30, 2025 and the remaining shares will vest in 24 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. |
| /s/ Jason Minio, Attorney-in-Fact | 09/11/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||